PALVELLA THERAPEUTICS, INC.
Palvella Therapeutics reported Phase 3 SELVA interview data showing improvements and high satisfaction with QTORIN rapamycin. The company also presented PK data with ≥40-fold lower exposure vs oral sirolimus and a claims analysis estimating 154,986 diagnosed DSAP patients in the U.S. according to the company.
Palvella Therapeutics (Nasdaq: PVLA) presented data at a dermatology conference. Phase 3 SELVA study results showed QTORIN™ rapamycin improved symptoms of microcystic lymphatic malformations (microcystic LMs) with high treatment satisfaction. A real-world claims analysis estimated 154,986 U.S. patients diagnosed with disseminated superficial actinic porokeratosis (DSAP) over eight years.
Oppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning PVLA (PALVELLA THERAPEUTICS, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent PVLA coverage spans financial news, insider activity and technology.
In the last 30 days, PVLA insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($3.0M). The most active reporter was JENKINS GEORGE M with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive Phase 3 data may drive the stock higher on expectations of FDA approval.
Positive clinical data and a large orphan disease market estimate may lift PVLA.
Slightly bearish rating may dampen sentiment.
Positive regulatory milestone likely to lift sentiment and support price gains.
Positive trial data and FDA funding likely boost investor sentiment and support a price rise.
AlphAI scores every news story that mentions PVLA with an AI model for sentiment and relevance, and aggregates insider trades from PALVELLA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Palvella Therapeutics reported Phase 3 SELVA interview data showing improvements and high satisfaction with QTORIN rapamycin. The company also presented PK data with ≥40-fold lower exposure vs oral sirolimus and a claims analysis estimating 154,986 diagnosed DSAP patients in the U.S. according to the company.
1 min readPalvella Therapeutics (Nasdaq: PVLA) presented data at a dermatology conference. Phase 3 SELVA study results showed QTORIN™ rapamycin improved symptoms of microcystic lymphatic malformations (microcystic LMs) with high treatment satisfaction. A real-world claims analysis estimated 154,986 U.S. patients diagnosed with disseminated superficial actinic porokeratosis (DSAP) over eight years.
2 min readOppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
2 min readPalvella Therapeutics (PVLA) is preparing for a potential 2027 U.S. launch of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations. The FDA awarded a third year of grant funding for the Phase 3 SELVA trial, and Palvella completed its New Drug Application in August. The company estimates over 30,000 U.S. patients have this rare condition, with no current FDA-approved therapies.
2 min readPalvella Therapeutics (PVLA) received FDA funding for its Phase 3 SELVA trial of QTORIN rapamycin for microcystic lymphatic malformations. The trial met all efficacy endpoints. The company plans a U.S. launch in 2027 if approved. PVLA stock closed at $138.16, up 0.97% in pre-market trading.
2 min readGoin Kathleen (Chief Operating Officer) sold 4,302 shares of PALVELLA THERAPEUTICS, INC. (PVLA) at an average of $152.24 ($151.16–$153.24, $0.65M total) across 3 trades on 2026-09-16 under a Rule 10b5-1 trading plan.
1 min readJENKINS GEORGE M sold 27,500 shares of PALVELLA THERAPEUTICS, INC. (PVLA) at an average of $151.53 ($149.38–$153.10, $4.17M total) across 9 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readPalvella Therapeutics (PVLA) completed its NDA submission to the FDA for QTORIN 3.9% rapamycin anhydrous gel, a potential treatment for microcystic lymphatic malformations (microcystic LMs). The NDA includes Phase 3 SELVA trial results, which met primary and secondary endpoints. The therapy has received Breakthrough Therapy, Fast Track, and Orphan Drug designations. Palvella anticipates a potential commercial launch in early 2027, pending approval.
2 min readGoin Kathleen (Chief Operating Officer) sold 4,302 shares of PALVELLA THERAPEUTICS, INC. (PVLA) at an average of $152.21 ($151.39–$156.77, $0.65M total) across 5 trades on 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readPALVELLA THERAPEUTICS, INC. (PVLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of
4 min read
